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Protein kinase B (PKB/Akt) activity is elevated in glioblastoma
cells due to mutation of the tumor suppressor PTEN/MMAC
Daphne Haas-Kogan*, Noga Shalev*, Michelle Wong†, Gordon Mills‡, 
Garret Yount* and David Stokoe†
Glioblastomas are highly malignant tumors of the
central nervous system that are resistant to radiation
and chemotherapy [1]. We explored the role of the
phosphatidylinositol (PI) 3-kinase signal transduction
pathway in glioblastomas, as this pathway has been
shown to inhibit apoptosis induced by cytokine
withdrawal and the detachment of cells from the
extracellular matrix [2]. Components of this pathway
have been implicated in tumor development [3–6]. We
show that glioblastoma cells, in contrast to primary
human astrocytes, contain high endogenous protein
kinase B (PKB/Akt) activity and high levels of PI 3,4,5-
triphosphate (PI(3,4,5)P3) and PI(3,4)P2, the lipid
products of PI 3-kinase. These glioblastoma cells
express mutant forms of the putative 3¢ phospholipid
phosphatase PTEN, also known as MMAC. Expression
of wild-type PTEN derived from primary astrocytes, but
not of mutant forms of PTEN, reduced the levels of
3¢ phosphoinositides and inhibited PKB/Akt activity.
PTEN antagonized the activation of PKB/Akt by
growth factors, by activated PI 3-kinase and by 
PI-dependent protein kinase-1 (PDK1), but did not
antagonize the phospholipid-independent activation
of PKB/Akt lacking the pleckstrin homology (PH)
domain. These results suggest a role for PTEN in
regulating the activity of the PI 3-kinase pathway in
malignant human cells.
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Results and discussion
We have shown previously that a number of glioblastoma
multiform (GM) cell lines are resistant to apoptosis
induced by ionizing radiation. One cell line, SF188, was
shown to undergo extensive radiation-induced apoptosis,
however [7]. These observations prompted us to examine
whether the activity of the PI 3-kinase pathway was differ-
entially regulated between these cell lines.
The activity of endogenous PKB/Akt in U87 MG cells, a
cell line that is markedly resistant to radiation-induced
apoptosis, is elevated relative to SF188 cells growing in
either serum-starved conditions or in the presence of 10%
serum (Figure 1a). In addition, phosphorylation of
PKB/Akt on Ser473, a residue implicated in the activation
of the kinase [8], is also increased in U87 MG cells com-
pared with SF188 cells (Figure 1a). The dramatic differ-
ence in PKB/Akt activity between these two cell lines led
us to extend this analysis to more GM cell lines. With the
exception of the SF188 cells, all of the seven GM cell
lines examined had elevated PKB/Akt activity relative to
human astrocytes, the normal cells from which glioblas-
tomas are derived. In each case, PKB/Akt activity was
abolished by pretreatment of the cells with the PI
3-kinase inhibitor LY294002 [9] (Figure 1b). Our data
show that in most GM tumor cells the PI 3-kinase–PKB
signal transduction pathway is dysregulated. To deter-
mine the level of dysregulation, we examined the levels of
3′ phosphorylated inositol phospholipids, the products of
PI 3-kinase activity. The levels of PI(3,4)P2 and
PI(3,4,5)P3 were increased in U87 MG cells compared
with either SF188 cells or primary astrocytes (Figure 1c),
indicating that the putative genetic abnormality lies
upstream of, or at the level of, PI 3-kinase. Addition of
LY294002 to U87 MG cells reduced the levels of these
phospholipids (Figure 1c). 
We sought to identify the genetic mutation leading to dys-
regulation of the PI 3-kinase–PKB pathway and investi-
gated whether mutations in the PTEN gene were
responsible. This tumor suppressor gene encodes a phos-
phatase and is located on chromosome 10q23. It has previ-
ously been shown to be mutated or deleted in several
human malignancies, including a large number of glioblas-
toma tumors [10]. Recent studies show that PTEN can
dephosphorylate the 3′ phosphate of PI(3,4,5)P3 in vitro
[11]. We therefore examined whether PTEN mutations
could explain the increased levels of 3′ phospholipids and
the increased PKB/Akt activity in GM cell lines. Several
of the cell lines shown in Figure 1 have previously been
shown to contain mutations or deletions in PTEN (U87
MG, U373 [12], U138 [13] and U251 [14]), which we con-
firmed. In addition, sequencing PTEN from the remaining
cell lines, SF188, SF126 and SF210, revealed two point
mutations in SF210 (I101T and K164R) and one point
mutation (G129R) in SF126. This latter mutation occurs
in the conserved phosphatase domain, has been found in
tumor specimens, and has been shown to abolish the
intrinsic phosphatase activity of PTEN in vitro [15]. We
found that the SF188 line — which had low levels of 3′
phospholipids and low PKB/Akt activity — expresses
wild-type PTEN. This is consistent with the hypothesis
that PTEN regulates PKB/Akt activity. Wild-type PTEN
derived from primary astrocytes expressed transiently in
U87 MG cells (Figure 2a) or stably in U87 MG cells and
U251 cells (Figure 2b) dramatically reduced PKB/Akt
activity and phosphorylation. In contrast, expression of the
mutant PTEN alleles derived from the GM cell lines
SF126 (Figure 2a) and U138, U251 and U373 (data not
shown) were unable to reduce PKB/Akt activity in U87
MG cells. PTEN derived from the SF210 line was still
able to reduce PKB/Akt activity, although to a lesser
extent than wild-type PTEN. Stable expression of
wild-type PTEN also reduced PKB/Akt activity in three
other GM cell lines expressing endogenous mutant
PTEN, but had no effect on the PKB/Akt activity in
SF188 cells (data not shown). These results indicate that
the high PKB/Akt activity in GM cell lines is a direct con-
sequence of inactivating PTEN mutations in these cells.
Stable expression of wild-type PTEN in U87 MG and
U251 cells also reduced the levels of the phospholipids
PI(3,4)P2 and PI(3,4,5)P3 (data not shown), confirming
that the target of PTEN is upstream of, or at the level of,
PI 3-kinase. The expression of wild-type PTEN inhibited
the proliferation of U87 MG cells, consistent with previ-
ous reports [14,16]. 
To further investigate the mechanism by which PTEN
reduces PKB/Akt activity, we examined the ability of
PTEN to antagonize the activation of PKB/Akt by differ-
ent stimuli. PTEN inhibited activation of PKB/Akt by
platelet-derived growth factor (PDGF), by an activated
version of PI 3-kinase (PI3K–CAAX), and by PDK1 in
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(c)
Activation of the PI 3-kinase pathway in GM cell lines. Cells were
grown in the absence or presence of serum (FBS) and treated with
LY294002 where indicated. (a) SF188 and U87 MG cell lysates were
immunoblotted using an antibody against PKB/Akt phosphorylated on
Ser473 (P-PKB), and immunoprecipitated using a rabbit polyclonal
antibody against the PKBα/Akt1 isoform. Half of the immune complex
was assayed for PKB/Akt activity using the peptide substrate crosstide
[8], and half was immunoblotted using the C-12 anti-PKBα antibody
(PKB). (b) The indicated glioblastoma cell lines were assayed for
PKB/Akt activity as described in (a). (c) Levels of PI(3,4)P2 (white
bars) and PI(3,4,5)P3 (grey bars) in the indicated cell lines.
both COS1 cells and NIH3T3 cells (Figure 3a,b). All
these agents require 3′ phospholipids for their ability to
activate PKB/Akt, as they are all inhibited by LY294002
(data not shown). The activation of a form of PKB lacking
its PH domain (∆PH-PKB) by PDK1 lacking its PH
domain (∆PH-PDK), which is less dependent on 3′ phos-
pholipids, was not affected by the expression of PTEN,
however (Figure 3c). Similarly, the activity and phospho-
rylation of ∆PH-PKB transiently expressed in U87 MG
cells was more resistant to inactivation by PTEN than
full-length PKB/Akt (Figure 3d). The resistance of ∆PH-
PKB to inactivation by PTEN is probably because ∆PH-
PKB is activated by PDK1 in a phospholipid-independent
manner [17,18], further reinforcing the role of PTEN in
controlling the PI 3-kinase–PKB pathway through the reg-
ulation of phospholipid levels.
The involvement of the PI 3-kinase pathway in inhibiting
apoptosis and promoting proliferation [19] suggests that this
signal transduction pathway has an important role in human
tumorigenesis. To date, however, dysregulation of this
pathway has been demonstrated in only a small subset of
human tumors through amplification of either PKBβ/Akt2
[5,6] or the catalytic subunit of PI 3-kinase, p110α (L.
Shayesteh, L. Yiling, W.-L. Kuo, R. Baldocchi, T. Godfrey,
C. Collins, D. Pinkel, G. Mills, J.W. Gray, unpublished
observations). Our finding that PTEN regulates PI(3,4,5)P3
lipid levels and PKB/Akt activity expands the role of the PI
3-kinase pathway in the development of a wide array of
human cancers. As PTEN mutations have been identified
in 60–70% of glioblastomas and advanced prostate cancers
as well as in several sporadic and familial malignancies [10],
our data implicate dysregulation of the PI 3-kinase pathway
as a key mediator of human carcinogenesis. 
Supplementary material
Additional methodological detail is published with this paper on the
internet.
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Figure 2
Expression of PTEN decreases PKB/Akt
activity in U87 MG and U251 cells. (a) U87
MG cells were transfected in duplicate with
hemagglutinin-tagged PKBα (HA–PKB) and
either empty vector or PTEN cloned from
primary astrocytes (1o ast.), SF210 or SF126
cells. Exogenous PKB/Akt was
immunoprecipitated with an anti-HA antibody.
The immune complex was assayed for
PKB/Akt activity, and immunoblotted with
antibodies against PKB/Akt phosphorylated
on either Ser473 (P-PKB S473), Thr308
(P-PKB T308) or with the C-12 anti-PKBα
antibody (PKB). An aliquot of each lysate was
also immunoblotted with the N-19 anti-PTEN
antibody (PTEN). (b) PKB/Akt activity in
stable U87 MG or U251 cell line pools
expressing PTEN (PTEN) or transformed with
empty vector (LXSN), grown in the absence
or presence of serum (FBS) and treated with
LY294002 where indicated. 
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(c)
PTEN antagonizes PKB/Akt activation by PI(3,4,5)P3-dependent
stimuli. (a) NIH3T3 cells were cotransfected with HA–PKB and the
indicated amounts of wild-type PTEN. PKB/Akt activity was assayed
following PDGF stimulation as described in Figure 1 and immune
complexes were immunoblotted with the C-12 anti-PKBα antibody
(HA–PKB). (b,c) COS1 cells were cotransfected with the indicated
plasmids and either HA–PKB or Glu–Glu-tagged ∆PH-PKB. PKB/Akt
was immunoprecipitated, assayed for kinase activity (PKB activity)
and immunoblotted with the C-12 anti-PKBα antibody (lower panels).
(d) U87 MG cells were transfected with either full-length HA–PKB
(PKB) or ∆PH-PKB, together with either empty vector, wild-type
PTEN from primary astrocytes (WT) or PTEN from SF126 cells
(G129R). Exogenous PKB/Akt was immunoprecipitated, and the
immune complex assayed for kinase activity (PKB activity), and
immunoblotted using antibodies against PKB/Akt phosphorylated on
either Ser473 (P-PKB S473) or Thr308 (P-PKB T308) or using the
C-12 anti-PKBα antibody (PKB). A portion of the lysate was also
probed with a PTEN antibody.
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Materials and methods
Cell culture and transfections
Cells were acquired and maintained as described [S1]. COS1 cells
and NIH3T3 cells were transfected using Lipofectamine Plus (Gibco)
and U87 MG cells were transfected with FuGene6 (Boehringer) follow-
ing the manufacturers’ instructions. For retroviral infections, 80% con-
fluent cells were infected with retrovirus expressing PTEN subcloned
into pLXSN and infected pools were selected and maintained in
500 µg/ml G418.
Plasmids and antibodies
HA-tagged PKB in pSG5 and a rabbit PKB/Akt C-12 antibody were
generous gifts from Boudewijn Burgering (Utrecht University).
PI3K–CAAX in pSG5 and Myc–PDK1 were donated by Pablo
Rodriguez-Viciana (University of California, San Francisco) and Phil
Hawkins (Babraham Institute). PTEN was amplified using the primers
5′-GCGCATGACAGCCATCATCAAAGA-3′ (forward) and 5′-
GCGCGCTCAGACTTTTGTAATTTG-3′ (reverse) and subcloned into
pcDNA3 or pLXSN. The antibody used to immunoprecipitate endoge-
nous PKB/Akt was raised against full-length Glu–Glu-tagged PKB/Akt
expressed in Sf9 cells. Immunoblotting of these immune complexes
was performed with a sheep C-12 peptide PKB/Akt antibody (Upstate
Biotechnology), and the Ser473 phospho-specific PKB/Akt antibody
was from New England Biolabs. The PTEN antibody was generously
donated by Nicholas Tonks (Cold Spring Harbor Laboratories).
Assay for PKB/Akt activity
Endogenous PKB/Akt activity was measured as described [17], with
the following modifications: 2 µl polyclonal antiserum generated
against full-length recombinant PKB/Akt and 25 µl 1:3 slurry of protein-
A–sepharose:PBS were used to immunoprecipitate endogenous
PKB/Akt, and a 16% tricine gel (Novex) was used to separate the sub-
strate peptide from free [32P]ATP. Activity was quantitated on a Storm
phosphorimager (Molecular Dynamics) and is expressed as arbitrary
units. The results from a single experiment are shown, although each
experiment was performed at least three times with identical results.
Measurement of PI(3,4,5)P3 and PI(3,4)P2 levels
Phospholipids were separated by HPLC essentially as described [S2].
The PI(3,4)P2 and PI(3,4,5)P3 peaks were identified from the migration
of lipids from COS cells expressing PI3K–CAAX or expressing PI
3-kinase together with Ras [S2].
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